Filing Details
- Accession Number:
- 0001203311-20-000100
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-09-02 19:24:50
- Reporting Period:
- 2020-08-31
- Accepted Time:
- 2020-09-02 19:24:50
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1060736 | Seattle Genetics Inc | SGEN | Biological Products, (No Disgnostic Substances) (2836) | 911874389 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1216477 | E Todd Simpson | 21823 30Th Drive Se Bothell WA 98021 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-08-31 | 2,065 | $155.69 | 140,489 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-08-31 | 2,122 | $155.69 | 138,367 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-09-01 | 4,452 | $155.25 | 133,915 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-09-01 | 5,480 | $155.74 | 128,435 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-09-01 | 1,640 | $156.87 | 126,795 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-09-01 | 50 | $157.82 | 126,745 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-09-01 | 469 | $159.33 | 126,276 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
- Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $154.49 to $155.46. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $155.52 to $156.27. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $156.58 to $157.54. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $159.32 to $159.34. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Billionaire Hedge Funds
